Form 13-F position report

FULCRUM THERAPEUTICS INC

Reported by MORGAN STANLEY

FULC CUSIP 359616109 Manager CIK 0000895421

Reported 165,623 shares, down 78,212 (32.1%) from the prior quarter.

Reported value -16.5%; share count -32.1% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q4 2025
Shares 165,623 Quarter-end amount reported
Reported value $1,873,196 Fair value at quarter end
Consecutive quarters held 26 Through Q4 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 1583000
2022-03-31 26215000
2022-06-30 5774000
2022-09-30 9710000
2022-12-31 8543888
2023-03-31 3312749
2023-06-30 3642785
2023-09-30 4048708
2023-12-31 8228649
2024-03-31 10923373
2024-06-30 7655841
2024-09-30 1251946
2024-12-31 7199140
2025-03-31 822525
2025-06-30 2163141
2025-09-30 2243282
2025-12-31 1873196
2026-03-31 1329495
2026-06-30 674143
2026-09-30 1228759

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for FULCRUM THERAPEUTICS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 332,097 +147,905 (80.3%) < 0.01% $1,228,759 2026-11-13
Q2 2026 Added 184,192 +10,855 (6.3%) < 0.01% $674,143 2026-08-13
Q1 2026 Added 173,337 +7,714 (4.7%) < 0.01% $1,329,495 2026-05-15
Q4 2025 Reduced 165,623 -78,212 (-32.1%) < 0.01% $1,873,196 2026-02-13
Q3 2025 Reduced 243,835 -70,575 (-22.4%) < 0.01% $2,243,282 2025-11-14
Q2 2025 Added 314,410 +28,811 (10.1%) < 0.01% $2,163,141 2025-08-15
Q1 2025 Reduced 285,599 -1,246,133 (-81.4%) < 0.01% $822,525 2025-05-15
Q4 2024 Added 1,531,732 +1,181,047 (336.8%) < 0.01% $7,199,140 2025-02-14
Q3 2024 Reduced 350,685 -884,128 (-71.6%) < 0.01% $1,251,946 2024-11-14
Q2 2024 Added 1,234,813 +77,676 (6.7%) < 0.01% $7,655,841 2024-08-14
Q1 2024 Reduced 1,157,137 -61,922 (-5.1%) < 0.01% $10,923,373 2024-05-15
Q4 2023 Added 1,219,059 +307,188 (33.7%) < 0.01% $8,228,649 2024-02-13
Q3 2023 Reduced 911,871 -192,003 (-17.4%) < 0.01% $4,048,708 2023-11-15
Q2 2023 Reduced 1,103,874 -58,494 (-5.0%) < 0.01% $3,642,785 2023-08-14
Q1 2023 Reduced 1,162,368 -11,243 (-1.0%) < 0.01% $3,312,749 2023-05-15
Q4 2022 Reduced 1,173,611 -26,618 (-2.2%) < 0.01% $8,543,888 2023-02-14
Q3 2022 Added 1,200,229 +21,628 (1.8%) < 0.01% $9,710,000 2022-11-14
Q2 2022 Added 1,178,601 +70,177 (6.3%) < 0.01% $5,774,000 2022-08-15
Q1 2022 Added 1,108,424 +1,018,955 (1138.9%) < 0.01% $26,215,000 2022-05-13
Q4 2021 Added 89,469 +4,458 (5.2%) < 0.01% $1,583,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

190 managers reported FULCRUM THERAPEUTICS INC for Q4 2025.

Managers reporting FULCRUM THERAPEUTICS INC in Q4 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
SUVRETTA CAPITAL MANAGEMENT LLC Added 6,561,111 +1,180,111 1.52% $74,206,165 20 qtrs
RA CAPITAL MANAGEMENT L P Reduced 6,053,960 -4,175,139 0.7% $68,470,288 14 qtrs
TCG Crossover Management LLC Unchanged 5,250,000 0 1.97% $59,377,500 6 qtrs
Nantahala Capital Management LLC Reduced 4,293,346 -377,438 1.61% $48,557,743 6 qtrs
BlackRock Inc Added 4,263,761 +557,011 < 0.01% $48,223,137 6 qtrs
VANGUARD GROUP INC Added 3,559,552 +560,088 < 0.01% $40,258,533 26 qtrs
BRAIDWELL LP Added 3,061,222 +2,841,734 1.11% $34,622,421 2 qtrs
Point72 Asset Management L P New 2,398,232 +2,398,232 0.03% $27,124,004 3 qtrs
Siren L L C New 1,950,000 +1,950,000 0.66% $22,054,500 1 qtr
D E Shaw & Co Inc Added 1,913,755 +464,332 0.01% $21,644,569 18 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2025
Filed
February 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
135,300
Shared
0
None
30,323

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.